ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/SMO
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/SMO
7
trial(s) found.
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
+ SMO inhibitor
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
+ SMO inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05150691
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (
DB-1303-O-1001
)
anti-ERBB2 antibody-drug conjugate
+ SMO inhibitor
HER2-positive solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT03534947
Curative
Phase 2
Recruiting
A Pilot Study to Evaluate Short Term Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinomas in Cosmetically Challenging Locations (
SONIB
)
SMO inhibitor,first generation
topical immune response modifier
Carcinoma
Cutaneous basal cell carcinoma
Skin cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
ACTRN12623000652673
Advanced
Phase 1
Recruiting
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-002 in Healthy Adult Volunteers: Part C Open-label Drug-Drug Interaction (
ELVN-002-002
)
ERBB2 inhibitor,exon 20 selective
+ SMO inhibitor
Non-small cell lung cancer
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6027 - Joondalup - Joondalup Health Campus
ACTRN12618001351202
Curative
Not Applicable
Not yet recruiting
A prospective case series evaluating neo-adjuvant use of Vismodegib in patients with periocular basal cell carcinoma to evaluate reduction in clinical and surgical tumour margins
SMO inhibitor,first generation
Cancer
Cutaneous basal cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ SMO inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Not yet recruiting (1)
Status unknown (1)
Recruitment Country and State
NSW (5)
VIC (2)
QLD (2)
WA (2)
SA (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Phase 2 (1)
Trial Type
Advanced (5)
Curative (2)
Cancer Therapy Class
SMO
100%
MET
29%
ERBB2
29%
B7H3
14%
ALK
14%
ATR
14%
BCR-ABL1
14%
CDK4
14%
CDK6
14%
CRAF
14%
EGFR
14%
FLT3
14%
JAK1
14%
JAK2
14%
KIT
14%
PDGFR
14%
PDGFRA
14%
PI3K
14%
RAF
14%
ROS1
14%
SRC
14%
VEGFR
14%
YES1
14%
mTOR
14%
mTORC1
14%
mTORC2
14%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2109 - North Ryde - Macquarie University Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
6027 - Joondalup - Joondalup Health Campus (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Head and neck cancer
Thoracic cancer
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
Skin cancer
Biliary tract cancer
Breast adenocarcinoma
Breast cancer
Epithelial Ovarian Cancer
Exocrine pancreatic cancer
Gastroesophageal cancer
Gastrointestinal cancer
Gynaecological cancer
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal cancer
Oesophageal squamous cell carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
HER2-positive solid tumour
Carcinoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy